Screening for Colon CancerMS-CareNCT06696534
Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme
A study testing Survey using a questionnaire. in people with Screening for Colon Cancer and Survey and Questionnaire, run by ADVANCED MARKER DISCOVERY S.L. at 2 sites in 2 countries.
Trial summary
The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years… Read more about this study
- Who is it for?
- Ages 50 to 69 yearsHealthy volunteers can take part
- Conditions the study is for
- Screening for Colon Cancer, Survey and Questionnaire
- What is being tested?
- Survey using a questionnaire.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 19 May 2025to Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 69 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
- Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
- Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
Who cannot join
- Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.
- Participants with a previous colonoscopy in consequence of a FOBT positive result.
- Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Portugal1 site, 1 recruiting
- Not yet recruiting
UCSP Sete Rios
Lisbon
Ana Rita, MD
Spain1 site, 1 recruiting
- Recruiting
CS Mar Báltico
Madrid, Madrid
Maria A Perez, MD
About this study
The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are:
- Values of experience of participants into screening programme.
- Values of preferences of participants for screening methods.
Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.
- Being tested
- Survey using a questionnaire.
- Keywords
- colorectal cancer, screening programme, experience, preference, questionnaire
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey using a questionnaire.Other
Preference questionnaire for colorectal cancer screening methods
Survey using a questionnaire.Other
Experience questionnaire into colorectal cancer screening programme
| Study group | Role | What they receive |
|---|---|---|
| FIT/FOBT population | Other | Average-risk population undergoing FIT/FOBT within the colorectal cancer screening programme. Receives: Other: Survey using a questionnaire. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Value of questionnaires into screening programme
The percentage of number of answers from each experience and preference questions
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2024
- Study start19 May 2025
- Primary completionNov 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Screening for Colon CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ADVANCED MARKER DISCOVERY S.L.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- SERMAS, ULS de Santa Maria
- Responsible party
- Sponsor
- Investigators
- Maria A Perez, MD, Principal investigator, Primary Health Care Centre Mar BálticoAna Rita, MD, Principal investigator, Unidade Local de Saúde Santa Maria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06696534
- Sponsor's protocol ID
- AMD-CCR-2024-01
- Other IDs
- 2024-NDMH-5101_240046
- Acronym
- MS-Care
- Status last verified
- Sep 2025
- First submitted
- 12 Nov 2024
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183.
PubMed 25326034De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S; EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Epub 2024 Jan 30.
PubMed 38307102Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
PubMed 36856579
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme
- ClinicalTrials.gov ID
- NCT06696534
- Acronym / sponsor ID
- MS-Care / AMD-CCR-2024-01
- Keywords
- colorectal cancer, screening programme, experience, preference, questionnaire
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- ADVANCED MARKER DISCOVERY S.L.Industry (pharma, biotech, devices)
- Collaborators
- SERMAS, ULS de Santa Maria
- Study start
- 19 May 2025 (actual)
- Primary completion
- Nov 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 20 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are:
- Values of experience of participants into screening programme.
- Values of preferences of participants for screening methods.
Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FIT/FOBT population | Other | Other: Survey using a questionnaire.Average-risk population undergoing FIT/FOBT within the colorectal cancer screening programme. |
Who may qualify
- Ages
- 50 to 69 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
- Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.
- Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
Key exclusion criteria (3 listed)
- Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.
- Participants with a previous colonoscopy in consequence of a FOBT positive result.
- Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey using a questionnaire.Preference questionnaire for colorectal cancer screening methods | Other | FIT/FOBT population |
| Survey using a questionnaire.Experience questionnaire into colorectal cancer screening programme | Other | FIT/FOBT population |
Primary outcome
Value of questionnaires into screening programme
Time frame: 12 months
The percentage of number of answers from each experience and preference questions
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Results publication: PubMed 25326034Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183.
- Results publication: PubMed 38307102De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S; EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Epub 2024 Jan 30.
- Results publication: PubMed 36856579Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
- Individual participant dataSharing planned: No
Related trials for Screening for Colon Cancer
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Not yet recruitingObservational study
European Implementation Study on Simultaneous Screening for Gastric and Colorectal Cancers
Helicobacter Pylori Infection, Colorectal Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruiting
Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening
Colorectal Cancer
Not yet recruiting
Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle East
Colonoscopy, Colorectal Cancer Screening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maria A Perez, MD principal investigator
Primary Health Care Centre Mar Báltico
Ana Rita, MD principal investigator
Unidade Local de Saúde Santa Maria
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Survey using a questionnaire. in people with Screening for Colon Cancer and Survey and Questionnaire, run by ADVANCED MARKER DISCOVERY S.L. at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Portugal, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marta Jimenez, PhD (+34 637899149, mjimenez@amadix.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Value of questionnaires into screening programme (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06696534, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.